Driehaus Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Driehaus Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,000	Closed	-$894K	–	566
2019 Q4	$894K	Hold	2,000	–	–	0.02%	311
2019 Q3	$615K	Hold	2,000	–	–	0.02%	388
2019 Q2	$636K	Buy	2,000 +1,500	+300%	+$519K	0.02%	343
2019 Q1	$210K	Buy	+500	New	+$201K	0.01%	381

Other funds holding EIGR

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Driehaus Capital Management's EIGR Position: Q1 2020 in Review

Driehaus Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2020, closing a stake of 2,000 shares — an estimated $894K sold.

Driehaus Capital Management first reported a position in EIGR in Q1 2019 and held it in 4 quarters. The position peaked at $894K in Q4 2019. 93 funds tracked by Wall St. Rank hold EIGR as of Q1 2020.

Driehaus Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Driehaus Capital Management sold 2,000 Eiger BioPharmaceuticals, Inc. shares in Q1 2020, an estimated $894K.
Driehaus Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2019 and held it in 4 quarters.
Driehaus Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $894K in Q4 2019.
93 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2020.

Based on Driehaus Capital Management's 13F filing for Q1 2020, filed 15 May 2020.